| Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia G Tsai, HY Lane, P Yang, MY Chong, N Lange Biological psychiatry 55 (5), 452-456, 2004 | 457 | 2004 |
| Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study HY Lane, YC Chang, YC Liu, CC Chiu, GE Tsai Archives of General Psychiatry 62 (11), 1196-1204, 2005 | 354 | 2005 |
| Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor HY Lane, CH Lin, MF Green, G Hellemann, CC Huang, PW Chen, R Tun, ... JAMA psychiatry 70 (12), 1267-1275, 2013 | 267 | 2013 |
| Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis B Galling, A Roldan, RE Nielsen, J Nielsen, T Gerhard, M Carbon, ... JAMA psychiatry 73 (3), 247-259, 2016 | 258 | 2016 |
| Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia CH Lin, CL Huang, YC Chang, PW Chen, CY Lin, GE Tsai, HY Lane Schizophrenia research 146 (1-3), 231-237, 2013 | 242 | 2013 |
| Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia HY Lane, CL Huang, PL Wu, YC Liu, YC Chang, PY Lin, PW Chen, G Tsai Biological psychiatry 60 (6), 645-649, 2006 | 225 | 2006 |
| An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 222 | 2022 |
| Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study HY Lane, YC Liu, CL Huang, YC Chang, CH Liau, CH Perng, GE Tsai Biological psychiatry 63 (1), 9-12, 2008 | 216 | 2008 |
| A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia HY Lane, CH Lin, YJ Huang, CH Liao, YC Chang, GE Tsai International Journal of Neuropsychopharmacology 13 (4), 451-460, 2010 | 212 | 2010 |
| Machine learning and systems genomics approaches for multi-omics data E Lin, HY Lane Biomarker research 5, 1-6, 2017 | 210 | 2017 |
| Risperidone-related weight gain: genetic and nongenetic predictors HY Lane, YC Liu, CL Huang, YC Chang, PL Wu, CT Lu, WH Chang Journal of clinical psychopharmacology 26 (2), 128-134, 2006 | 200 | 2006 |
| Variant GADL1 and Response to Lithium Therapy in Bipolar I Disorder CH Chen, CS Lee, MTM Lee, WC Ouyang, CC Chen, MY Chong, JY Wu, ... New England Journal of Medicine 370 (2), 119-128, 2014 | 199 | 2014 |
| Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics HY Lane, YC Chang, WH Chang, SK Lin, YT Tseng, MW Jann Journal of Clinical Psychiatry 60 (1), 36-40, 1999 | 192 | 1999 |
| Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease CH Chang, CH Lin, HY Lane International journal of molecular sciences 22 (5), 2761, 2021 | 187 | 2021 |
| Association of Risperidone Treatment Response With a Polymorphism in the 5-HT2A Receptor Gene HY Lane, YC Chang, CC Chiu, ML Chen, MH Hsieh, WH Chang American Journal of Psychiatry 159 (9), 1593-1595, 2002 | 181 | 2002 |
| Genome-wide association study of bipolar I disorder in the Han Chinese population MTM Lee, CH Chen, CS Lee, CC Chen, MY Chong, WC Ouyang, NY Chiu, ... Molecular psychiatry 16 (5), 548-556, 2011 | 179 | 2011 |
| Glutamate signaling in the pathophysiology and therapy of schizophrenia CH Lin, HY Lane, GE Tsai Pharmacology Biochemistry and Behavior 100 (4), 665-677, 2012 | 178 | 2012 |
| d-glutamate and Gut Microbiota in Alzheimer’s Disease CH Chang, CH Lin, HY Lane International journal of molecular sciences 21 (8), 2676, 2020 | 171 | 2020 |
| Brain stimulation in Alzheimer's disease CH Chang, HY Lane, CH Lin Frontiers in psychiatry 9, 201, 2018 | 171 | 2018 |
| Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances ML Lu, HY Lane, SK Lin, KP Chen, WH Chang Journal of Clinical Psychiatry 65 (6), 766-771, 2004 | 171 | 2004 |
